Search results
Results from the WOW.Com Content Network
Fibrinogen (coagulation factor I) is a glycoprotein complex, produced in the liver, [1] that circulates in the blood of all vertebrates. [2] During tissue and vascular injury, it is converted enzymatically by thrombin to fibrin and then to a fibrin-based blood clot. Fibrin clots function primarily to occlude blood vessels to stop bleeding ...
This acidification causes the precipitation of certain clotting factors in a complex called the euglobulin fraction. The euglobulin fraction contains the important fibrinolytic factors fibrinogen, PAI-1, tissue plasminogen activator (tPA), plasminogen, and to a lesser extent α 2-antiplasmin. The euglobulin fraction also contains factor VIII.
If a coagulation factor is part of the contact activation or tissue factor pathway, a deficiency of that factor will affect only one of the tests: Thus hemophilia A, a deficiency of factor VIII, which is part of the contact activation pathway, results in an abnormally prolonged aPTT test but a normal PT test. Deficiencies of common pathway ...
The thrombin time (TT), also known as the thrombin clotting time (TCT), is a blood test that measures the time it takes for a clot to form in the plasma of a blood sample containing anticoagulant, after an excess of thrombin has been added. [1] It is used to diagnose blood coagulation disorders and to assess the effectiveness of fibrinolytic ...
FDPs compete with thrombin, and thus slow down clot formation by preventing the conversion of fibrinogen to fibrin. This effect can be seen in the thrombin clotting time (TCT) test, which is prolonged in a person that has active fibrinolysis. FDPs, and a specific FDP, the D-dimer, can be measured using antibody-antigen technology. This is more ...
EXTEM test mildly activates haemostasis via the physiological activator tissue factor. The result is influenced by extrinsic coagulation factors, platelets and fibrinogen. EXTEM is a screening test for the (extrinsic) haemostasis system. This assay is not influenced by heparin (heparin inhibitor included in the EXTEM reagent).
D-dimer formation. Shown are fibrinogen, with its one E domain and two D domains, acted upon in cascade, by the following enzymes: Thrombin, to create a mesh of fibrin protofibrils; Factor XIII to crosslink the fibrin mesh (linking protofibril D domains), the scaffold for clot formation; Plasmin, whose action in fibrinolysis produces fibrin degradation products (FDPs), the smallest of which ...
The results of these screening tests, in conjunction with the clinical history (especially bleeding history), will then direct the selection of further, more detailed and specific coagulation tests, such as: specific factor assays, like fibrin degradation products, D-dimer, thrombin time, platelet aggregation, or